CNS Early Assets AurimMed is a development-stage, CNS-focused small-molecule company aiming to advance assets through Phase I to partner or license for Phase II/III. This structure creates clear sales angles for large pharma seeking early-stage candidates to fill their CNS pipelines.

Co-Development Path The business model centers on agreements with larger companies to co-develop through Phase II/III or to license the products for commercialization. This aligns with buyers' risk-sharing preferences and can support milestone- and royalty-based deals.

Indication Expansion Lead compounds target CNS indications like anticonvulsants, neuropathic pain analgesics, and neuroprotectives, with potential broader use in anxiety, depression, insomnia, schizophrenia, Parkinson’s, and bipolar disorder. This broad signal can help identify potential licensees across neurology, psychiatry, and neurodegenerative brands.

Outsourcing Readiness With a lean team (2-10 employees), AurimMed will rely on external R&D, regulatory, and manufacturing support. This creates a sales opportunity to offer dedicated development partnerships, CRO/CDMO collaborations, and flexible resourcing arrangements to scale quickly for a license or co-development deal.

Financial Entry Point Current revenue is zero to under one million, indicating an early-stage asset with potentially high upside for partners willing to fund or co-fund development. Approach discussions with risk-sharing milestones, upfronts, and royalty structures aligned to clinical progress and regulatory pathways.